IDIA.SW Stock — Price, Charts & Analysis

Idorsia Ltd (IDIA.SW) has no trailing P/E shown and a forward P/E of 104.66x. This places IDIA.SW in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

IDIA.SW trades with 104.66x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether IDIA.SW looks overvalued or undervalued.

IDIA.SW's P/E of 104.66x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

IDIA.SW's trailing EPS is -CHF 1.38 and forward EPS is CHF 0.06.

EPS, or earnings per share, shows how much profit Idorsia Ltd generated for each share. IDIA.SW's trailing EPS is -CHF 1.38, and investors usually prefer EPS that is positive and growing over time.

Idorsia Ltd has a market cap of CHF 1.54B, making IDIA.SW a small-cap stock based on the current market value shown on Worldtickers.

IDIA.SW's latest stock price on Worldtickers is CHF 5.79. The latest move is CHF 0.16 or 2.84%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

IDIA.SW's quote includes a latest price of CHF 5.79. The market open is CHF 5.55. Previous close is CHF 5.63. The intraday range is CHF 5.51 to CHF 5.84.

IDIA.SW is up in the latest quote, with a move of CHF 0.16 or 2.84%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

IDIA.SW generated CHF 199.71M in trailing revenue. Revenue growth is -26.80%, which helps show whether demand is expanding or slowing.

IDIA.SW's revenue growth is -26.80%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, IDIA.SW does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -CHF 316.18M.

Gross margin is 31.54%. Margins show how efficiently Idorsia Ltd turns revenue into profit.

Idorsia Ltd carries CHF 1.32B and holds CHF 88.69M in cash.

IDIA.SW holds CHF 88.69M on its balance sheet.

IDIA.SW's book value per share is -CHF 4.54.

Institutions hold 26.82% of IDIA.SW shares. Insiders hold 30.74% of shares. Ownership mix helps investors understand how much of Idorsia Ltd is held by professional investors and company insiders.

IDIA.SW has 265.12M shares outstanding. Float shares are 166.55M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for IDIA.SW, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for IDIA.SW is CHF 0.06. Revenue growth is -26.80%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

IDIA.SW's trailing EPS is -CHF 1.38. Forward EPS is CHF 0.06. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

IDIA.SW is in the Healthcare sector. Its earnings multiple is 104.66x. Its latest displayed growth metric is -26.80%. Compare these figures with sector peers before deciding whether Idorsia Ltd is stronger or weaker than average.

IDIA.SW trades at CHF 5.79. The stock trades at 104.66x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Idorsia Ltd's fundamentals.

IDIA.SW risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.66, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

IDIA.SW should be compared with companies in Biotechnology. Its earnings multiple is 104.66x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Idorsia Ltd (IDIA.SW) operates in Healthcare, specifically Biotechnology. Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which

IDIA.SW trades on Swiss. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

IDIA.SW stock is priced in CHF on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Idorsia Ltd's official website listed on Worldtickers is www.idorsia.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Idorsia Ltd employs about 424 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Idorsia Ltd is headquartered in Allschwil, Switzerland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

IDIA.SW is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

IDIA.SW has traded between CHF 2.42 and CHF 7.56 over the past 52 weeks. At CHF 5.79, it is 23.41% below the high and 139.75% above the low. The 52-week range helps gauge long-term price momentum.

IDIA.SW is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is CHF 6.00 and its 200-day moving average is CHF 4.28.

IDIA.SW's RSI is 42.23. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

IDIA.SW's latest RSI reading is 42.23, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for IDIA.SW is near CHF 5.49. Key resistance is near CHF 6.94. Breaks above resistance or below support can change the short-term technical setup.

IDIA.SW's nearest reported support level is CHF 5.49. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

IDIA.SW's nearest reported resistance level is CHF 6.94. A breakout above resistance can improve momentum, especially when volume confirms the move.

IDIA.SW trades about 1.72M shares daily on average. The latest displayed volume is 803.79K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

IDIA.SW's MACD is -0.06, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

IDIA.SW is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 42.23 (neutral). MACD is bearish. Nearest support is around CHF 5.49. Resistance is around CHF 6.94. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is CHF 6.14 (-8.38% from price). MA50 is CHF 6.00 (-6.14% from price). MA200 is CHF 4.28 (31.58% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. IDIA.SW's MA20 is CHF 6.14. MA50 is CHF 6.00. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

IDIA.SW's pivot is near CHF 5.95. Support is near CHF 5.49. Resistance is near CHF 6.94. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for IDIA.SW is near CHF 4.74. The next upper resistance zone is near CHF 6.32. These levels help define risk and possible follow-through zones after a breakout or breakdown.

IDIA.SW's Bollinger range is roughly CHF 5.51 to CHF 6.78. Band width is near 20.75%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

IDIA.SW's ATR-based typical daily range is about 7.14%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 803.79K shares. Average volume is about 1.72M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

IDIA.SW's all-time high shown on Worldtickers is CHF 33.43. Its all-time low is CHF 0.61. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

IDIA.SW has a beta of 1.66, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.